John Zarosky, MD
Family Medicine · Bedford, TXNPI 1568626646
Payments from drug & device makers
Across 199 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$388
- Pfizer$305
- AbbVie$303
- Abbott$236
- Amarin Pharma, Inc.$218
- AstraZeneca$205
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,280100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 23 | $388 |
| Pfizer | 18 | $305 |
| AbbVie(2 entities) | 21 | $303 |
| Abbott | 12 | $236 |
| Amarin Pharma, Inc. | 12 | $218 |
| AstraZeneca | 14 | $205 |
| GSK | 10 | $191 |
| Bayer | 11 | $171 |
| Lilly USA, LLC | 11 | $166 |
| Novo Nordisk | 9 | $158 |
| Astellas Pharma US Inc | 9 | $140 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $93 |
| Amgen | 4 | $69 |
| Exact Sciences | 2 | $58 |
| Johnson & Johnson | 4 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $53 |
| Dexcom, Inc. | 3 | $45 |
| Novartis | 3 | $45 |
| Scilex Pharmaceuticals Inc. | 2 | $42 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Optinose US, Inc. | 2 | $32 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Merck | 2 | $25 |
| Medtronic | 1 | $23 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $23 |
| Genentech USA, Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
How this compares
$3,286 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 68 | $101,130 |
| GlyxambiEmpagliflozin/Linagliptin | 38 | $60,113 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $60,103 |
| OzempicSemaglutide | 56 | $53,000 |
| XareltoRivaroxaban | 32 | $50,538 |
| JardianceEmpagliflozin | 30 | $39,913 |
| JanuviaSitagliptin Phosphate | 32 | $38,160 |
| CreonLipase/Protease/Amylase | 11 | $36,250 |
| TradjentaLinagliptin | 16 | $23,399 |
| MounjaroTirzepatide | 18 | $20,624 |
| Rosuvastatin Calcium | 422 | $5,512 |
| Atorvastatin Calcium | 411 | $5,507 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $4,414 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $4,365 |
| Gabapentin | 195 | $4,003 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimGlyxambi, Jardiance, Tradjenta | $388 | $123,42584 claims |
| PfizerEliquis | $305 | $101,13068 claims |
| GSKTrelegy Ellipta | $191 | $60,10378 claims |
| Novo NordiskOzempic | $158 | $53,00056 claims |
| Johnson & JohnsonXarelto | $53 | $50,53832 claims |
| AbbVieCreon, Synthroid | $303 | $38,90331 claims |
| MerckJanuvia | $25 | $38,16032 claims |
| Lilly USA, LLCMounjaro | $166 | $20,62418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Bedford
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.